INDP
Indaptus Therapeutics, Inc.NASDAQHealthcare$1.75+9.37%ClosedMarket Cap: $3.1M
As of 2026-04-07
Valuation
P/E (TTM)
—
PEG
—
P/B
1.20
P/S
0.00
EV/EBITDA
0.26
DCF Value
$8.29
FCF Yield
-499.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-938.7%
ROA
-223.9%
ROIC
-629.3%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | NaN% | $-8.2M | $-8.1M | $-3.74 | — |
| FY 2025 | $0.00 | NaN% | $-19.8M | $-20.8M | $-21.58 | — |
| Q3 2025 | $0.00 | NaN% | $-2.6M | $-3.0M | $-2.98 | — |
| Q2 2025 | $0.00 | NaN% | $-4.5M | $-5.2M | $-9.10 | — |
| Q1 2025 | $0.00 | NaN% | $-4.6M | $-4.5M | $-0.48 | — |
| Q4 2024 | $0.00 | NaN% | $-4.2M | $-4.1M | $-0.38 | — |
| FY 2024 | $0.00 | NaN% | $-15.4M | $-15.0M | $-1.61 | — |
| Q3 2024 | $0.00 | NaN% | $-3.1M | $-3.1M | $-0.32 | — |
| Q2 2024 | $0.00 | NaN% | $-4.1M | $-4.0M | $-0.47 | — |
| Q1 2024 | $0.00 | NaN% | $-3.9M | $-3.8M | $-0.45 | — |
| Q4 2023 | $0.00 | NaN% | $-4.2M | $-4.0M | $-0.48 | — |
| FY 2023 | $0.00 | NaN% | $-16.4M | $-15.4M | $-1.84 | — |